BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20559334)

  • 1. Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model.
    Lee JM; Yoon SH; Kim HS; Kim SY; Sohn HJ; Oh ST; Oh IH; Kim TG
    Cancer Gene Ther; 2010 Oct; 17(10):742-50. PubMed ID: 20559334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
    Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
    Hess SD; Egilmez NK; Shiroko J; Bankert RB
    Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.
    Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL
    J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
    Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
    Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
    Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
    J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
    Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
    J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.
    Egilmez NK; Hess SD; Chen FA; Takita H; Conway TF; Bankert RB
    Cancer Res; 2002 May; 62(9):2611-7. PubMed ID: 11980657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
    Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
    Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
    Lin X; Chen X; Wei Y; Zhao J; Fan L; Wen Y; Wu H; Zhao X
    Gynecol Oncol; 2007 Mar; 104(3):540-6. PubMed ID: 17112567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR).
    Yoon SH; Lee JM; Woo SJ; Park MJ; Park JS; Kim HS; Park MY; Sohn HJ; Kim TG
    J Clin Immunol; 2009 Nov; 29(6):806-14. PubMed ID: 19517218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Lim J; Kang JS; Park SK; Lee K; Kim JY; Kim YJ; Hong JT; Kim Y; Han SB
    Int Immunopharmacol; 2009 Mar; 9(3):375-80. PubMed ID: 19105981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.